Acute myeloid leukemia after PARP inhibitor treatment in ovarian cancer—a case report and literature review

Jing Zeng, Jianrong Wu, Qingli Li, Kemin Li, Danqing Wang, Rutie Yin
{"title":"Acute myeloid leukemia after PARP inhibitor treatment in ovarian cancer—a case report and literature review","authors":"Jing Zeng, Jianrong Wu, Qingli Li, Kemin Li, Danqing Wang, Rutie Yin","doi":"10.21037/gpm-22-34","DOIUrl":null,"url":null,"abstract":"Background: Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) are widely used in the maintenance therapy of ovarian cancer. First-line maintenance therapy with PARPi increases overall survival in patients with ovarian cancer. However, the occurrence of rare and delayed adverse events, including cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), should alert researchers and clinicians.","PeriodicalId":92781,"journal":{"name":"Gynecology and pelvic medicine","volume":"41 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and pelvic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/gpm-22-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPi) are widely used in the maintenance therapy of ovarian cancer. First-line maintenance therapy with PARPi increases overall survival in patients with ovarian cancer. However, the occurrence of rare and delayed adverse events, including cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), should alert researchers and clinicians.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卵巢癌PARP抑制剂治疗后急性髓性白血病1例报告并文献复习
背景:聚二磷酸腺苷核糖聚合酶抑制剂(PARP)广泛应用于卵巢癌的维持治疗。一线维持治疗PARPi增加卵巢癌患者的总生存期。然而,罕见和延迟不良事件的发生,包括骨髓增生异常综合征(MDS)和急性髓性白血病(AML)的病例,应该引起研究人员和临床医生的注意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A survey in Liangshan, Sichuan showed higher human papillomavirus infection rate and cervical cancer risk for Yi Chinese compared to Han Chinese Commentary on “Age and postoperative opioid use in women undergoing pelvic organ prolapse surgery” Intrauterine vacuum-induced hemorrhage-control device for hemorrhage after myomectomy: a case report and review of the literature Polymorphism and pelvic organ prolapse: combining strict inclusion criteria and environmental risk factors as a good standard for further studies Evaluation and management of urinary incontinence in nursing home residents: unique considerations for an at-risk population
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1